Prostate Cancer: Symptoms, PSA Test, Diagnosis and Treatment Options

Prostate cancer is one of the important health conditions affecting men, particularly as age increases. One of the challenges is that early prostate cancer often does not cause noticeable symptoms. Urinary symptoms can also be caused by common non-cancerous conditions such as benign prostatic hyperplasia (BPH). This is why evaluation may involve risk assessment, PSA testing, examination, imaging and, when appropriate, prostate biopsy rather than relying on symptoms alone.

Prostate cancer develops when abnormal cells in the prostate grow in an uncontrolled way. Some prostate cancers grow slowly, while others can be more aggressive and spread beyond the prostate. The appropriate approach depends on factors such as the cancer's grade, stage, PSA level, overall health and individual circumstances.

Early-stage prostate cancer often does not cause symptoms. When symptoms do occur, they can include difficulty starting urination, a weak or interrupted urine stream, frequent urination, blood in the urine or semen, or discomfort in the pelvic area. These symptoms are not specific to cancer and can also occur with BPH, prostatitis or other urinary conditions.

Frequent urination by itself does not mean that a man has prostate cancer. BPH, urinary infection, overactive bladder, diabetes and other conditions can cause similar urinary symptoms. In fact, early prostate cancer commonly causes no symptoms. Persistent or new urinary symptoms should still be evaluated rather than assumed to be caused by prostate enlargement or cancer.

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate that becomes more common with age. BPH can cause urinary symptoms such as a weak stream, difficulty starting urination, urgency and frequent nighttime urination. Prostate cancer is a separate condition involving abnormal cancerous cells. Having BPH does not mean that a man has prostate cancer.

PSA stands for prostate-specific antigen, a protein produced by prostate cells. A PSA blood test measures the amount of PSA in the blood. PSA can be elevated in prostate cancer, but also in non-cancerous conditions such as BPH and prostatitis. Therefore, a raised PSA does not by itself diagnose prostate cancer.

No. PSA can rise because of prostate cancer, but it can also increase because of BPH, prostatitis and other prostate-related conditions. A single elevated PSA result should not automatically be interpreted as cancer. Depending on the situation, a urologist may recommend repeating the test, evaluating other clinical factors, using imaging or proceeding to biopsy.

A prostate biopsy involves taking small tissue samples from the prostate so that a pathologist can examine them for cancer cells. A biopsy is used to confirm the diagnosis when clinical findings, PSA and imaging indicate that cancer may be present. The biopsy report also provides information about the grade of the cancer, which helps guide treatment decisions.

The Gleason grading system describes how abnormal prostate cancer cells look under a microscope. Modern reports commonly also use Grade Groups to communicate the aggressiveness of the cancer. This information is combined with PSA, clinical findings and the extent of disease to help determine risk and treatment options.

Treatment depends on the stage, Grade Group, PSA level, risk category, overall health and personal circumstances. Options can include active surveillance for selected localised cancers, surgery, radiation therapy and hormone therapy. Advanced disease may require systemic treatments such as androgen-deprivation therapy, chemotherapy, targeted therapy or other treatments depending on the cancer's characteristics.

Many prostate cancers that are detected while still localised can be treated with curative intent. The outlook depends heavily on the cancer's stage, grade, PSA level and other risk characteristics. Advanced or metastatic prostate cancer is managed differently, with treatment focused on controlling the disease, extending survival and maintaining quality of life.

Yes. Prostate cancer can spread beyond the prostate, including to bones and lymph nodes. When staging suggests that cancer may have spread, additional imaging may be recommended. Treatment for metastatic prostate cancer is different from treatment for cancer confined to the prostate and may involve hormone therapy combined with other systemic treatments.

No. BPH is a benign enlargement of the prostate and is not cancer. Both conditions can occur in the same person and can produce overlapping urinary symptoms. This is why persistent urinary symptoms or an abnormal PSA should be properly evaluated rather than assumed to be caused by BPH alone.

A urology evaluation is appropriate when a man has persistent urinary symptoms, blood in the urine or semen, an abnormal or rising PSA, an abnormal prostate examination, a strong family history of prostate cancer, or concerns about prostate cancer risk. Early evaluation can help determine whether further testing is appropriate.

If you have an abnormal PSA, urinary symptoms, a family history of prostate cancer or concerns about prostate cancer screening, a urologist can assess your individual risk and explain which tests are appropriate.